Table 4.
DRUG Time of exposure | No. (%) of cases | No. (%) of controls | OR (95% CI) | OR Adg (95% CI) * |
---|---|---|---|---|
NIMESULIDE | ||||
<15 days | 25 (13.97) | 176 (9.94) | 1.66 (1.03–2.68) | 1.89 (1.12–3.20) |
15–30 days | 2 (1.12) | 5 (0.28) | 4.82 (0.92–25.34) | 4.89 (0.80–30.00) |
>30 days | 3 (1.68) | 3 (0.17) | 16.05 (2.60–98.94) | 12.55 (1.73–90.88) |
ASA | ||||
<15 days | 7 (3.93) | 76 (4.30) | 0.93 (0.42–2.08) | 1.06 (0.45–2.50) |
15–30 days | 1 (0.56) | 1 (0.06) | 10.60 (0.66–169.75) | 6.31 (0.37–106.38) |
>30 days | 22 (12.36) | 173 (9.79) | 1.40 (0.83–2.35) | 1.66 (0.93–2.96) |
KETOPROFEN | ||||
<15 days | 18 (10.06) | 173 (9.77) | 0.94 (0.54–1.64) | 1.05 (0.57–1.93) |
15–30 days | 1 (0.56) | 2 (0.11) | 4.97 (0.45–54.87) | 6.55 (0.56–76.66) |
>30 days | 0 (0) | 2 (0.11) | NA | NA |
IBUPROFEN | ||||
<15 days | 23 (12.85) | 162 (9.16) | 1.52 (0.92–2.50) | 1.89 (1.09–3.26) |
15–30 days | 1 (0.56) | 4 (0.23) | 2.57 (0.29–23.05) | 2.53 (0.26–24.69) |
>30 days | 1 (0.56) | 3 (0.17) | 3.46 (0.36–33.29) | 2.58 (0.25–26.95) |
DICLOFENAC | ||||
<15 days | 10 (5.59) | 74 (4.19) | 1.42 (0.70–2.87) | 1.35 (0.63–2.92) |
15–30 days | 1 (0.56) | 3 (0.17) | 3.47 (0.36–33.40) | 4.23 (0.40–45.07) |
>30 days | 1 (0.56) | 4 (0.23) | 2.58 (0.29–23.13) | 4.66 (0.49–44.15) |
PARACETAMOL | ||||
<15 days | 61 (34.08) | 286 (16.16) | 3.08 (2.14–4.43) | 2.66 (1.83–3.88) |
15–30 days | 3 (1.68) | 7 (0.40) | 6.01 (1.51–23.89) | 5.25 (1.21–22.82) |
>30 days | 5 (2.79) | 6 (0.34) | 14.78 (3.90–56.00) | 18.36 (4.60–73.34) |
See methods sections for details of adjustment